Treatment of Liver Metastases in Patients with Neuroendocrine Tumors of Gastroesophageal and Pancreatic Origin
Well-to-moderately differentiated neuroendocrine tumors of gastroesophageal and pancreatic origin (GEP-NETs) with liver metastasis are a heterogeneous group of malignancies for which a range of therapeutic options have been employed. Surgical resection of hepatic metastases or hepatic artery emboliz...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | International Journal of Hepatology |
| Online Access: | http://dx.doi.org/10.1155/2012/131659 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832557017704693760 |
|---|---|
| author | Ping Gu Jennifer Wu Elliot Newman Franco Muggia |
| author_facet | Ping Gu Jennifer Wu Elliot Newman Franco Muggia |
| author_sort | Ping Gu |
| collection | DOAJ |
| description | Well-to-moderately differentiated neuroendocrine tumors of gastroesophageal and pancreatic origin (GEP-NETs) with liver metastasis are a heterogeneous group of malignancies for which a range of therapeutic options have been employed. Surgical resection of hepatic metastases or hepatic artery embolization may be beneficial in patients with hepatic-predominant metastatic disease. Patients with “carcinoid” syndrome and syndromes associated with functional pancreatic NET (PNET) can be effectively treated with somatostatin analogs. On the other hand, the efficacy of systemic chemotherapy for these patients is limited. A placebo-controlled, double-blind, prospective, and randomized study showed that octreotide LAR improves progression-free survival in patients with advanced midgut functional “carcinoids.” In patients with advanced pancreatic NET, randomized, placebo-controlled studies have recently demonstrated that treatment with the tyrosine kinase inhibitor sunitinib or with mTOR inhibitor everolimus is associated with improved progression-free survival. Based on these studies, octreotide LAR, sunitinib, or everolimus are now considered as first-line therapeutic options in patients with advanced NET. Future studies will likely further define the role of these agents in patients with carcinoid liver metastasis and pancreatic NET liver metastasis. |
| format | Article |
| id | doaj-art-51e0c848885848fdad2530b84d2422c7 |
| institution | Kabale University |
| issn | 2090-3448 2090-3456 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Hepatology |
| spelling | doaj-art-51e0c848885848fdad2530b84d2422c72025-02-03T05:43:43ZengWileyInternational Journal of Hepatology2090-34482090-34562012-01-01201210.1155/2012/131659131659Treatment of Liver Metastases in Patients with Neuroendocrine Tumors of Gastroesophageal and Pancreatic OriginPing Gu0Jennifer Wu1Elliot Newman2Franco Muggia3Department of Hematology and Medical Oncology, NYU Cancer Institute, New York, NY 10016, USADepartment of Hematology and Medical Oncology, NYU Cancer Institute, New York, NY 10016, USADepartment of General Surgery, NYU Medical Center New York, NY 10016, USADepartment of Medical Oncology, NYU Cancer Institute, New York, NY 10016, USAWell-to-moderately differentiated neuroendocrine tumors of gastroesophageal and pancreatic origin (GEP-NETs) with liver metastasis are a heterogeneous group of malignancies for which a range of therapeutic options have been employed. Surgical resection of hepatic metastases or hepatic artery embolization may be beneficial in patients with hepatic-predominant metastatic disease. Patients with “carcinoid” syndrome and syndromes associated with functional pancreatic NET (PNET) can be effectively treated with somatostatin analogs. On the other hand, the efficacy of systemic chemotherapy for these patients is limited. A placebo-controlled, double-blind, prospective, and randomized study showed that octreotide LAR improves progression-free survival in patients with advanced midgut functional “carcinoids.” In patients with advanced pancreatic NET, randomized, placebo-controlled studies have recently demonstrated that treatment with the tyrosine kinase inhibitor sunitinib or with mTOR inhibitor everolimus is associated with improved progression-free survival. Based on these studies, octreotide LAR, sunitinib, or everolimus are now considered as first-line therapeutic options in patients with advanced NET. Future studies will likely further define the role of these agents in patients with carcinoid liver metastasis and pancreatic NET liver metastasis.http://dx.doi.org/10.1155/2012/131659 |
| spellingShingle | Ping Gu Jennifer Wu Elliot Newman Franco Muggia Treatment of Liver Metastases in Patients with Neuroendocrine Tumors of Gastroesophageal and Pancreatic Origin International Journal of Hepatology |
| title | Treatment of Liver Metastases in Patients with Neuroendocrine Tumors of Gastroesophageal and Pancreatic Origin |
| title_full | Treatment of Liver Metastases in Patients with Neuroendocrine Tumors of Gastroesophageal and Pancreatic Origin |
| title_fullStr | Treatment of Liver Metastases in Patients with Neuroendocrine Tumors of Gastroesophageal and Pancreatic Origin |
| title_full_unstemmed | Treatment of Liver Metastases in Patients with Neuroendocrine Tumors of Gastroesophageal and Pancreatic Origin |
| title_short | Treatment of Liver Metastases in Patients with Neuroendocrine Tumors of Gastroesophageal and Pancreatic Origin |
| title_sort | treatment of liver metastases in patients with neuroendocrine tumors of gastroesophageal and pancreatic origin |
| url | http://dx.doi.org/10.1155/2012/131659 |
| work_keys_str_mv | AT pinggu treatmentoflivermetastasesinpatientswithneuroendocrinetumorsofgastroesophagealandpancreaticorigin AT jenniferwu treatmentoflivermetastasesinpatientswithneuroendocrinetumorsofgastroesophagealandpancreaticorigin AT elliotnewman treatmentoflivermetastasesinpatientswithneuroendocrinetumorsofgastroesophagealandpancreaticorigin AT francomuggia treatmentoflivermetastasesinpatientswithneuroendocrinetumorsofgastroesophagealandpancreaticorigin |